Alberto Izzotti
Overview
Explore the profile of Alberto Izzotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
3082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Perrone U, Evangelisti G, Lagana A, Bogliolo S, Ceccaroni M, Izzotti A, et al.
Expert Opin Emerg Drugs
. 2023 Dec;
28(4):333-351.
PMID: 38099328
Introduction: Endometriosis is an estrogen-dependent disease that gives rise to pelvic pain and infertility. Although estroprogestins and progestins currently stand as the first-line treatments for this condition, demonstrating efficacy in...
12.
Kussainova A, Bulgakova O, Aripova A, Ibragimova M, Pulliero A, Begimbetova D, et al.
J Pers Med
. 2023 Nov;
13(11).
PMID: 38003914
Asbestos is a known carcinogen; however, the influence of chrysotile asbestos on the development of tumor-related diseases remains a subject of intense debate within the scientific community. To analyze the...
13.
Etrusco A, Barra F, Chiantera V, Ferrero S, Bogliolo S, Evangelisti G, et al.
Drugs
. 2023 Oct;
83(17):1595-1611.
PMID: 37837497
Adenomyosis, characterized by the growth of endometrial tissue within the uterine wall, poses significant challenges in treatment. The literature primarily focuses on managing abnormal uterine bleeding (AUB) and dysmenorrhea, the...
14.
Khalid Z, Coco S, Ullah N, Pulliero A, Cortese K, Varesano S, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686579
Background: Oncolytic viruses (OVs) have been utilized since 1990s for targeted cancer treatment. Our study examined the Measles-Mumps-Rubella (MMR) vaccine's cancer-killing potency against Glioblastoma (GBM), a therapy-resistant, aggressive cancer type....
15.
Pulliero A, Mastracci L, Tarantini L, Khalid Z, Bollati V, Izzotti A
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511536
Background: Let-7 is a tumor suppressor microRNA targeting the KRAS lung oncogene. Let-7a downregulation is reversible during the early stages of lung carcinogenesis but is irreversible in cancer cells. The...
16.
Velkova I, Pasino M, Khalid Z, Menichini P, Martorana E, Izzotti A, et al.
J Pers Med
. 2023 May;
13(5).
PMID: 37240889
Ferroptosis is a cell death pathway triggered by an imbalance between the production of oxidants and antioxidants, which plays an emerging role in tumorigenesis. It is mainly regulated at three...
17.
Barra F, Perrone U, Ferrero S, Gustavino C, Bogliolo S, Izzotti A
J Reprod Immunol
. 2023 May;
158:103967.
PMID: 37229887
This letter discusses the article "The Effects of Rituximab on Experimental Endometriosis Model in Rats" by Dogan et al., which evaluated the potential therapeutic efficacy of rituximab in an experimental...
18.
Varesano S, Pulliero A, Martorana E, Pizzino G, Raciti G, Coco S, et al.
J Pers Med
. 2023 Mar;
13(3).
PMID: 36983713
Human papillomavirus (HPV) is causatively associated with cervical cancer, the fourth most common malignant disease of women worldwide: (1) The aim of the proposed study is to implement routine diagnostics...
19.
Traversi D, Calabro G, Francese C, Franchitti E, Pulliero A, Spatera P, et al.
J Prev Med Hyg
. 2023 Feb;
63(3 Suppl 2):E1-E29.
PMID: 36818497
No abstract available.
20.
Izzotti A
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612131
Despite the impressive progress of therapies in recent years, cancer still remains the second leading cause of death in developed countries [...].